Express News | Biodexa Pharmaceuticals Highlights Phase 2 Data Results For ERapa

Benzinga08:23 ET

Promising Phase 2 Results For Biodexa's ERapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

CARDIFF, UK / ACCESSWIRE / June 3, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) just announced promising phase 2 results for its newly in-licensed drug eRapa for treating familial adenomatous polyposi

Accesswire08:00 ET

European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower

European equities traded in the US as American depositary receipts rose Friday morning, gaining 0.61% to 1,418.20 on the S&P Europe Select ADR Index. The index is poised to end the week lower. From co

MT NewswiresMay 31 11:11 ET

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading

European equities traded in the US as American depositary receipts were trending modestly higher late Thursday morning, rising 0.35% to 1,408.14 on the S&P Europe Select ADR Index. From continental Eu

MT NewswiresMay 30 11:10 ET

European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were moving sharply lower Wednesday morning, falling 1.39% to 1,402.95 on the S&P Europe Select ADR Index. Gainers in continental Eur

MT NewswiresMay 29 11:11 ET

Biodexa Pharmaceuticals Unveils Series G Warrant

TipRanksMay 28 18:01 ET